Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.57 |
| ▸ | AKT2 | P31751 | 4/20 | 0.57 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16131658 | 0.89 | AKT1 (0.59) | AKT1AKT2AKT3ACHEBACE1 | |
| SCHEMBL926441 | 0.83 | AKT1 (0.56) | AKT1AKT2AKT3 | |
| SCHEMBL27919558 | 0.83 | AKT1 (0.56) | AKT1AKT2AKT3 | |
| SCHEMBL12194067 | 0.83 | AKT2 (0.52) | AKT1AKT2AKT3KMT2ALRRK2 | |
| SCHEMBL3117947 | 0.82 | AKT1 (0.56) | AKT1AKT2AKT3KMT2AACHE | |
| SCHEMBL27905414 | 0.82 | AKT1 (0.56) | AKT1AKT2AKT3KMT2AACHE | |
| SCHEMBL3128336 | 0.82 | AKT1 (0.48) | AKT1AKT2AKT3KMT2ALRRK2 | |
| SCHEMBL16131657 | 0.79 | AKT1 (0.49) | AKT1AKT2AKT3ACHEBACE1 | |
| SCHEMBL3434915 | 0.79 | AKT1 (0.42) | AKT1AKT2AKT3KMT2AACHE | |
| SCHEMBL27905417 | 0.79 | AKT1 (0.57) | AKT1AKT2AKT3ACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409886-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160152601-A9 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-06-02 | — | — | US | disclosed |
| EP-2170863-B1 | Pyrimido cyclopentanes useful for the treatment of inflammatory or hyperproliferative diseases | ARRAY BIOPHARMA INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20140080829-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8618097-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| CN-103288753-A | Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC | 2013-09-11 | — | — | CN | disclosed |
| CN-101631778-B | Cyclopenta [ D ] pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC | 2013-05-08 | — | — | CN | disclosed |
| US-20110015204-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080829-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | AKT1 3/4885AKT2 4/4885AKT3 8/4885 |
| US-20160152601-A9 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | AKT1 3/4885AKT2 4/4885AKT3 8/4885 |
| US-20110015204-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | AKT1 3/4885AKT2 4/4885AKT3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.